(NASDAQ: PTGX) Protagonist Therapeutics's forecast annual revenue growth rate of -11.2% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.43%.
Protagonist Therapeutics's revenue in 2026 is $281,992,000.On average, 16 Wall Street analysts forecast PTGX's revenue for 2026 to be $35,291,251,556, with the lowest PTGX revenue forecast at $27,172,950,120, and the highest PTGX revenue forecast at $40,025,956,770. On average, 16 Wall Street analysts forecast PTGX's revenue for 2027 to be $10,513,802,147, with the lowest PTGX revenue forecast at $4,085,422,282, and the highest PTGX revenue forecast at $18,820,404,692.
In 2028, PTGX is forecast to generate $19,989,036,319 in revenue, with the lowest revenue forecast at $6,209,924,695 and the highest revenue forecast at $34,128,443,675.